umirolimus (Biolimus) Report issue

Small molecule Experimental
AACT MeSH PubChem

Active Ingredient History

NOW
  • Now
Umirolimus is an immunosuppressant, a macrocyclic lactone, a highly lipophilic derivative of sirolimus. This drug is proprietary to Biosensors International, which uses it in its own drug-eluting stents, and licenses it to partners such as Terumo.   Wikipedia

Chemistry

  • SMILES: CCOCCO[C@@H]1CC[C@@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@@H](OC)C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)C[C@H]1OC
  • InChIKey: YYSFXUWWPNHNAZ-PKJQJFMNSA-N
  • Mol. Mass: 986.29
  • ALogP: 7.24
  • ChEMBL Molecule:
    umirolimus  
More Chemistry

Pharmacology

Alternative names

40-o-(2-ethoxyethyl)rapamycin | 42-o-(2-ethoxyethyl) rapamycin | biolimus | biolimus a9 | rapamycin, 42-o-(2-ethoxyethyl)- | trm-986 | umirolimus

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (1)


 

Coronary Restenosis

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Acute Coronary Syndrome (Phase 4)

Death (Phase 4)

Hemorrhage (Phase 4)

Hypertension (Phase 4)

Myocardial Infarction (Phase 4)

Myocardial Ischemia (Phase 4)

Organ Transplantation ()

Stroke (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue